{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:47:59Z","timestamp":1792169279462,"version":"4.4.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To identify and prioritize key factors influencing clinicians' selection of BoNT formulations for chronic spasticity treatment to inform future guidelines and standardize decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Modified two-round Delphi study with international spasticity management experts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting:<\/jats:title>\n                    <jats:p>International survey involving clinicians from various practice settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants:<\/jats:title>\n                    <jats:p>Round 1: 108 clinicians rating decision factors; Round 2: 55 respondents ranking factors. Convenience sampling of international spasticity experts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures:<\/jats:title>\n                    <jats:p>Importance ratings of seven decision-making categories using 5-point Likert scales (Round 1) and factor ranking (Round 2). Inter-rater agreement assessed using Kendall's coefficient of concordance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Respondents primarily used onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA. Round 1 identified economic factors as most important (mean 3.74 points), followed by hospital\/system factors (3.53 points) and toxin-specific factors (3.27 points). Round 2 revealed disease-specific factors as highest priority (14 first-place votes, mean rank 3.42 points), followed by injector expertise and toxin characteristics. Kendall's coefficient was 0.35, indicating moderate agreement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>BoNT formulation selection involves multiple factors with significant practice variability. While economic and institutional considerations influence decisions, clinicians prioritize disease characteristics, clinical expertise, and toxin properties when ranking options. Evidence-based guidelines are needed to reduce practice variation and improve BoNT-based spasticity management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/phm.0000000000002861","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:00:08Z","timestamp":1781733608000},"page":"S897-S903","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Factors Influencing the Selection of Botulinum Toxin Preparations for the Management of Spasticity"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6056-7250","authenticated-orcid":false,"given":"Peter D.","family":"Vu","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Korupolu","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas"},{"name":"TIRR Memorial Hermann Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"B. Ivanhoe","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas"},{"name":"TIRR Memorial Hermann Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas"},{"name":"TIRR Memorial Hermann Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-1916","authenticated-orcid":false,"given":"Gerard E.","family":"Francisco","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas"},{"name":"TIRR Memorial Hermann Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"R1-20261016","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/15459683211011214","article-title":"A new definition of poststroke spasticity and the interference of spasticity with motor recovery from acute to chronic stages","volume":"35","author":"Li","year":"2021","journal-title":"Neurorehabil Neural Repair"},{"key":"R2-20261016","doi-asserted-by":"crossref","first-page":"17562864211070657","DOI":"10.1177\/17562864211070657","article-title":"Evidence of treating spasticity before it develops: a systematic review of spasticity outcomes in acute spinal cord injury interventional trials","volume":"15","author":"Stampas","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"R3-20261016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijge.2018.05.005","article-title":"Post-stroke spasticity: a review of epidemiology, pathophysiology, and treatments","volume":"12","author":"Kuo","year":"2018","journal-title":"Int J Gerontol"},{"key":"R4-20261016","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/jpm12050808","article-title":"Spasticity management after spinal cord injury: the here and now","volume":"12","author":"Billington","year":"2022","journal-title":"J Pers Med"},{"key":"R5-20261016","doi-asserted-by":"crossref","first-page":"jrm00134","DOI":"10.2340\/16501977-2753","article-title":"A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: an international group consensus","volume":"53","author":"Francisco","year":"2021","journal-title":"J Rehabil Med"},{"key":"R6-20261016","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"R7-20261016","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/CCID.S156851","article-title":"Botulinum neurotoxin formulations: overcoming the confusion","volume":"11","author":"Samizadeh","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R8-20261016","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"R9-20261016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.zefq.2022.04.025","article-title":"Reporting guidelines for Delphi techniques in health sciences: a methodological review","volume":"172","author":"Spranger","year":"2022","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"R10-20261016","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1590\/abd1806-4841.20143705","article-title":"Sample size: how many participants do I need in my research?","volume":"89","author":"Mart\u00ednez-Mesa","year":"2014","journal-title":"An Bras Dermatol"},{"key":"R11-20261016","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1540-5915.1997.tb01330.x","article-title":"Managing Delphi surveys using nonparametric statistical techniques*","volume":"28","author":"Schmidt","year":"1997","journal-title":"Decision Sciences"},{"key":"R12-20261016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12911-019-1003-9","article-title":"Selection process for botulinum toxin injections in patients with chronic-stage hemiplegic stroke: a qualitative study","volume":"19","author":"Arai","year":"2019","journal-title":"BMC Med Inform Decis Mak"},{"key":"R13-20261016","first-page":"199","article-title":"Botulinum toxin type A injections for pediatric spasticity: Keeping our patients informed and practices safe","volume":"14","author":"Wright","year":"2021","journal-title":"J Pediatr Rehabil Med"},{"key":"R14-20261016","doi-asserted-by":"crossref","first-page":"e067268","DOI":"10.1136\/bmjopen-2022-067268","article-title":"Integrating patient values and preferences in healthcare: a systematic review of qualitative evidence","volume":"12","author":"Tringale","year":"2022","journal-title":"BMJ Open"},{"key":"R15-20261016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/HMR.0000000000000254","article-title":"Evidence-based practice and patient-centered care: Doing both well","volume":"46","author":"Engle","year":"2021","journal-title":"Health Care Manage Rev"},{"key":"R16-20261016","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/pmrj.13211","article-title":"AAPM&R consensus guidance on spasticity assessment and management","volume":"16","author":"Verduzco-Gutierrez","year":"2024","journal-title":"PM&R"},{"key":"R17-20261016","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol Rev"},{"key":"R18-20261016","first-page":"97","article-title":"Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries","volume":"5","author":"Roze","year":"2012","journal-title":"Med Devices Evid Res"},{"key":"R19-20261016","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.nrleng.2019.10.011","article-title":"Descriptive analysis of the annual cost of treating spasticity with different types of botulinum toxin A","volume":"37","author":"Hern\u00e1ndez Herrero","year":"2022","journal-title":"Neurolog\u00eda (Engl Ed)"},{"key":"R20-20261016","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40120-024-00692-9","article-title":"Treatment patterns and healthcare costs among patients with stroke and spasticity: a 2-year longitudinal study","volume":"14","author":"Hull","year":"2025","journal-title":"Neurol Ther"},{"key":"R21-20261016","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1007\/s12325-023-02563-5","article-title":"Botulinum toxin utilization, treatment patterns, and healthcare costs among patients with spasticity or cervical dystonia in the US","volume":"40","author":"Hull","year":"2023","journal-title":"Adv Ther"}],"container-title":["American Journal of Physical Medicine &amp; Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PHM.0000000000002861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:00:29Z","timestamp":1792166429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PHM.0000000000002861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":21,"journal-issue":{"issue":"11S","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/phm.0000000000002861","relation":{},"ISSN":["0894-9115","1537-7385"],"issn-type":[{"value":"0894-9115","type":"print"},{"value":"1537-7385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"2025-06-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}